Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George J Hutton

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Preventive Medicine|November 18, 2024
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United StatesJieni Li, George J Hutton, Tyler J Varisco, et al.
Patient Preference and Adherence|November 12, 2020
Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple SclerosisJagadeswara R Earla, George J Hutton, J Douglas Thornton, et al.
Pharmacotherapy|February 28, 2021
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosisJagadeswara R Earla, George J Hutton, Douglas J Thornton, et al.
Exploratory Research in Clinical and Social Pharmacy|April 28, 2022
Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosisJagadeswara Rao Earla, George J Hutton, J Douglas Thornton, et al.
Pediatrics|October 8, 2008
Spectrum of pediatric neuromyelitis opticaTimothy E Lotze, Jennifer L Northrop, George J Hutton, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimodPaul Schurmann, Sukhdeep Basra, Omar G Awar, et al.
International Journal of MS Care|January 24, 2014
The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosisJose Avila-Ornelas, Mirla Avila, Milena Stosic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 9, 2004
Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosisYing C Q Zang, Sheri M Skinner, Rachel R Robinson, et al.
Frontiers in Human Neuroscience|December 15, 2010
Functional brain network changes associated with maintenance of cognitive function in multiple sclerosisSantosh A Helekar, Jae C Shin, Brandi J Mattson, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 30, 2026
Characteristics of myelin oligodendrocyte glycoprotein antibody-associated meningoencephalitisAisha Elfasi, Samir Alkabie, Elsa Rodriguez, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Preventive Medicine|November 18, 2024
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United StatesJieni Li, George J Hutton, Tyler J Varisco, et al.
Patient Preference and Adherence|November 12, 2020
Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple SclerosisJagadeswara R Earla, George J Hutton, J Douglas Thornton, et al.
Pharmacotherapy|February 28, 2021
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosisJagadeswara R Earla, George J Hutton, Douglas J Thornton, et al.
Exploratory Research in Clinical and Social Pharmacy|April 28, 2022
Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosisJagadeswara Rao Earla, George J Hutton, J Douglas Thornton, et al.
Pediatrics|October 8, 2008
Spectrum of pediatric neuromyelitis opticaTimothy E Lotze, Jennifer L Northrop, George J Hutton, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimodPaul Schurmann, Sukhdeep Basra, Omar G Awar, et al.
International Journal of MS Care|January 24, 2014
The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosisJose Avila-Ornelas, Mirla Avila, Milena Stosic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 9, 2004
Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosisYing C Q Zang, Sheri M Skinner, Rachel R Robinson, et al.
Frontiers in Human Neuroscience|December 15, 2010
Functional brain network changes associated with maintenance of cognitive function in multiple sclerosisSantosh A Helekar, Jae C Shin, Brandi J Mattson, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 30, 2026
Characteristics of myelin oligodendrocyte glycoprotein antibody-associated meningoencephalitisAisha Elfasi, Samir Alkabie, Elsa Rodriguez, et al.
Pageof 5